PLB1001
Phase 3Small molecule
PLB1001 is one of 92 small molecule programs targeting MET Exon 14 Mutation. It is currently in Phase 3.
3
Indications
5
Total Trials
3
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1TQB2450
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Nanocrystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
JMT101
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
PLB1001
BBeijing Pearl Biotechnology Limited Liability Company
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
MET Exon 14 Mutation1 trial
Non-Small Cell Lung Cancer1 trial
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
Active, not recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 2·NCT04258033·145 enrolled
Glioblastoma1 trial
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Active, not recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 2/3·NCT06105619·84 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PLB1001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details